Skip to main content
Top
Published in: PharmacoEconomics 9/2016

Open Access 01-09-2016 | Systematic Review

Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer

Authors: Pieter T. de Boer, Geert W. J. Frederix, Talitha L. Feenstra, Pepijn Vemer

Published in: PharmacoEconomics | Issue 9/2016

Login to get access

Abstract

Background

Transparent reporting of validation efforts of health economic models give stakeholders better insight into the credibility of model outcomes. In this study we reviewed recently published studies on seasonal influenza and early breast cancer in order to gain insight into the reporting of model validation efforts in the overall health economic literature.

Methods

A literature search was performed in Pubmed and Embase to retrieve health economic modelling studies published between 2008 and 2014. Reporting on model validation was evaluated by checking for the word validation, and by using AdViSHE (Assessment of the Validation Status of Health Economic decision models), a tool containing a structured list of relevant items for validation. Additionally, we contacted corresponding authors to ask whether more validation efforts were performed other than those reported in the manuscripts.

Results

A total of 53 studies on seasonal influenza and 41 studies on early breast cancer were included in our review. The word validation was used in 16 studies (30 %) on seasonal influenza and 23 studies (56 %) on early breast cancer; however, in a minority of studies, this referred to a model validation technique. Fifty-seven percent of seasonal influenza studies and 71 % of early breast cancer studies reported one or more validation techniques. Cross-validation of study outcomes was found most often. A limited number of studies reported on model validation efforts, although good examples were identified. Author comments indicated that more validation techniques were performed than those reported in the manuscripts.

Conclusions

Although validation is deemed important by many researchers, this is not reflected in the reporting habits of health economic modelling studies. Systematic reporting of validation efforts would be desirable to further enhance decision makers’ confidence in health economic models and their outcomes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Caro JJ, Briggs AH, Siebert U, Kuntz KM, ISPOR-SMDM modeling good research practices task force. Modeling good research practices—overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value Health. 2012;15:796–803.PubMedCrossRef Caro JJ, Briggs AH, Siebert U, Kuntz KM, ISPOR-SMDM modeling good research practices task force. Modeling good research practices—overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value Health. 2012;15:796–803.PubMedCrossRef
2.
go back to reference Cash D, Clark WC, Alcock F, Dickson NM, Eckley N, Jäger J. Salience, credibility, legitimacy and boundaries: linking research, assessment and decision making. RWP02-046. Cambridge, MA: John F. Kennedy School of Government, Harvard University; 2002. Cash D, Clark WC, Alcock F, Dickson NM, Eckley N, Jäger J. Salience, credibility, legitimacy and boundaries: linking research, assessment and decision making. RWP02-046. Cambridge, MA: John F. Kennedy School of Government, Harvard University; 2002.
3.
go back to reference van Voorn GA, Vemer P, Hamerlijnck D, Ramos IC, Teunissen GJ, Al M, Feenstra TL. The Missing Stakeholder Group: why patients should be involved in health economic modelling. Appl Health Econ Health Policy. 2016;14:129–33.PubMedCrossRef van Voorn GA, Vemer P, Hamerlijnck D, Ramos IC, Teunissen GJ, Al M, Feenstra TL. The Missing Stakeholder Group: why patients should be involved in health economic modelling. Appl Health Econ Health Policy. 2016;14:129–33.PubMedCrossRef
4.
go back to reference Dams J, Bornschein B, Reese JP, Conrads-Frank A, Oertel WH, Siebert U, et al. Modelling the cost effectiveness of treatments for Parkinson’s disease: a methodological review. Pharmacoeconomics. 2011;29:1025–49.PubMedCrossRef Dams J, Bornschein B, Reese JP, Conrads-Frank A, Oertel WH, Siebert U, et al. Modelling the cost effectiveness of treatments for Parkinson’s disease: a methodological review. Pharmacoeconomics. 2011;29:1025–49.PubMedCrossRef
5.
go back to reference Bolin K. Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models. Pharmacoeconomics. 2012;30:551–64.PubMedCrossRef Bolin K. Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models. Pharmacoeconomics. 2012;30:551–64.PubMedCrossRef
6.
go back to reference Rochau U, Schwarzer R, Jahn B, Sroczynski G, Kluibenschaedl M, Wolf D, et al. Systematic assessment of decision-analytic models for chronic myeloid leukemia. Appl Health Econ Health Policy. 2014;12:103–15.PubMedCrossRef Rochau U, Schwarzer R, Jahn B, Sroczynski G, Kluibenschaedl M, Wolf D, et al. Systematic assessment of decision-analytic models for chronic myeloid leukemia. Appl Health Econ Health Policy. 2014;12:103–15.PubMedCrossRef
7.
go back to reference Leung HW, Chan AL, Leung MS, Lu CL. Systematic review and quality assessment of cost-effectiveness analysis of pharmaceutical therapies for advanced colorectal cancer. Ann Pharmacother. 2013;47:506–18.PubMedCrossRef Leung HW, Chan AL, Leung MS, Lu CL. Systematic review and quality assessment of cost-effectiveness analysis of pharmaceutical therapies for advanced colorectal cancer. Ann Pharmacother. 2013;47:506–18.PubMedCrossRef
8.
go back to reference Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics. 2008;26:191–215.PubMedCrossRef Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics. 2008;26:191–215.PubMedCrossRef
9.
go back to reference Afzali HHA, Gray J, Karnon J. Model performance evaluation (validation and calibration) in model-based studies of therapeutic interventions for cardiovascular diseases: a review and suggested reporting framework. Appl Health Econ Health Policy. 2013;11:85–93.CrossRef Afzali HHA, Gray J, Karnon J. Model performance evaluation (validation and calibration) in model-based studies of therapeutic interventions for cardiovascular diseases: a review and suggested reporting framework. Appl Health Econ Health Policy. 2013;11:85–93.CrossRef
10.
go back to reference Carrasco LR, Jit M, Chen MI, Lee VJ, Milne GJ, Cook AR. Trends in parameterization, economics and host behaviour in influenza pandemic modelling: a review and reporting protocol. Emerg Themes Epidemiol. 2013;10:3.PubMedPubMedCentralCrossRef Carrasco LR, Jit M, Chen MI, Lee VJ, Milne GJ, Cook AR. Trends in parameterization, economics and host behaviour in influenza pandemic modelling: a review and reporting protocol. Emerg Themes Epidemiol. 2013;10:3.PubMedPubMedCentralCrossRef
11.
go back to reference Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, ISPOR-SMDM Modeling Good Research Practices Task Force, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5. Value Health. 2012;15:828–34.PubMedCrossRef Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, ISPOR-SMDM Modeling Good Research Practices Task Force, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5. Value Health. 2012;15:828–34.PubMedCrossRef
14.
go back to reference Vemer P, van Voom GA, Ramos IC, Krabbe PF, Al MJ, Feenstra TL. Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM Modeling Good Research Practices Task Force. Value Health. 2013;16:1106–7.PubMedCrossRef Vemer P, van Voom GA, Ramos IC, Krabbe PF, Al MJ, Feenstra TL. Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM Modeling Good Research Practices Task Force. Value Health. 2013;16:1106–7.PubMedCrossRef
15.
go back to reference Vemer P, Ramos IC, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34:349–61.PubMedCrossRef Vemer P, Ramos IC, van Voorn GA, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34:349–61.PubMedCrossRef
16.
go back to reference Chilcott J, Tappenden P, Rawdin A, Johnson M, Kaltenthaler E, Paisley S, et al. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review. Health Technol Assess. 2010;14:iii–iv, ix–xii, 1–107. Chilcott J, Tappenden P, Rawdin A, Johnson M, Kaltenthaler E, Paisley S, et al. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review. Health Technol Assess. 2010;14:iii–iv, ix–xii, 1–107.
17.
go back to reference Baguelin M, Jit M, Miller E, Edmunds WJ. Health and economic impact of the seasonal influenza vaccination programme in England. Vaccine. 2012;30:3459–62.PubMedCrossRef Baguelin M, Jit M, Miller E, Edmunds WJ. Health and economic impact of the seasonal influenza vaccination programme in England. Vaccine. 2012;30:3459–62.PubMedCrossRef
18.
go back to reference Beigi RH, Wiringa AE, Bailey RR, Assi TM, Lee BY. Economic value of seasonal and pandemic influenza vaccination during pregnancy. Clin Infect Dis. 2009;49:1784–92.PubMedPubMedCentralCrossRef Beigi RH, Wiringa AE, Bailey RR, Assi TM, Lee BY. Economic value of seasonal and pandemic influenza vaccination during pregnancy. Clin Infect Dis. 2009;49:1784–92.PubMedPubMedCentralCrossRef
19.
go back to reference Blommaert A, Bilcke J, Vandendijck Y, Hanquet G, Hens N, Beutels P. Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium. Vaccine. 2014;32:6075–83.PubMedCrossRef Blommaert A, Bilcke J, Vandendijck Y, Hanquet G, Hens N, Beutels P. Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium. Vaccine. 2014;32:6075–83.PubMedCrossRef
20.
go back to reference Brydak L, Roiz J, Faivre P, Reygrobellet C. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis. Clin Drug Invest. 2012;32:73–85.CrossRef Brydak L, Roiz J, Faivre P, Reygrobellet C. Implementing an influenza vaccination programme for adults aged ≥65 years in Poland: a cost-effectiveness analysis. Clin Drug Invest. 2012;32:73–85.CrossRef
21.
go back to reference Chen S, Liao C. Cost-effectiveness of influenza control measures: a dynamic transmission model-based analysis. Epidemiol Infect. 2013;141:2581–94.PubMedCrossRef Chen S, Liao C. Cost-effectiveness of influenza control measures: a dynamic transmission model-based analysis. Epidemiol Infect. 2013;141:2581–94.PubMedCrossRef
22.
go back to reference Chit A, Roiz J, Briquet B, Greenberg DP. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors. Vaccine. 2015;33:734–41.PubMedCrossRef Chit A, Roiz J, Briquet B, Greenberg DP. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors. Vaccine. 2015;33:734–41.PubMedCrossRef
23.
go back to reference Clements KM, Chancellor J, Nichol K, DeLong K, Thompson D. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States. Value Health. 2011;14:800–11.PubMedCrossRef Clements KM, Chancellor J, Nichol K, DeLong K, Thompson D. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States. Value Health. 2011;14:800–11.PubMedCrossRef
24.
go back to reference Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccin Immunother. 2014;10:1171–80.PubMedPubMedCentralCrossRef Clements KM, Meier G, McGarry LJ, Pruttivarasin N, Misurski DA. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States. Hum Vaccin Immunother. 2014;10:1171–80.PubMedPubMedCentralCrossRef
25.
go back to reference Damm O, Eichner M, Rose MA, Knuf M, Wutzler P, Liese JG, et al. Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. Eur J Health Econ. 2015;16:471–88.PubMedCrossRef Damm O, Eichner M, Rose MA, Knuf M, Wutzler P, Liese JG, et al. Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. Eur J Health Econ. 2015;16:471–88.PubMedCrossRef
26.
go back to reference Ding Y, Zangwill KM, Hay JW, Allred NJ, Yeh SH. Cost-benefit analysis of in-hospital influenza vaccination of postpartum women. Obstet Gynecol. 2012;119:306–14.PubMedCrossRef Ding Y, Zangwill KM, Hay JW, Allred NJ, Yeh SH. Cost-benefit analysis of in-hospital influenza vaccination of postpartum women. Obstet Gynecol. 2012;119:306–14.PubMedCrossRef
27.
go back to reference Dugas AF, Coleman S, Gaydos CA, Rothman RE, Frick KD. Cost-utility of rapid polymerase chain reaction-based influenza testing for high-risk emergency department patients. Ann Emerg Med. 2013;62:80–8.PubMedPubMedCentralCrossRef Dugas AF, Coleman S, Gaydos CA, Rothman RE, Frick KD. Cost-utility of rapid polymerase chain reaction-based influenza testing for high-risk emergency department patients. Ann Emerg Med. 2013;62:80–8.PubMedPubMedCentralCrossRef
28.
go back to reference Fisman DN, Tuite AR. Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada. PLoS One. 2011;6:e27420.PubMedPubMedCentralCrossRef Fisman DN, Tuite AR. Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada. PLoS One. 2011;6:e27420.PubMedPubMedCentralCrossRef
29.
go back to reference Giglio N, Gentile A, Lees L, Micone P, Armoni J, Reygrobellet C, et al. Public health and economic benefits of new pediatric influenza vaccination programs in Argentina. Hum Vaccines Immunother. 2012;8:302–12.CrossRef Giglio N, Gentile A, Lees L, Micone P, Armoni J, Reygrobellet C, et al. Public health and economic benefits of new pediatric influenza vaccination programs in Argentina. Hum Vaccines Immunother. 2012;8:302–12.CrossRef
30.
go back to reference Jit M, Cromer D, Baguelin M, Stowe J, Andrews N, Miller E. The cost-effectiveness of vaccinating pregnant women against seasonal influenza in England and Wales. Vaccine. 2010;29:115–22.PubMedCrossRef Jit M, Cromer D, Baguelin M, Stowe J, Andrews N, Miller E. The cost-effectiveness of vaccinating pregnant women against seasonal influenza in England and Wales. Vaccine. 2010;29:115–22.PubMedCrossRef
31.
go back to reference Lavelle TA, Uyeki TM, Prosser LA. Cost-effectiveness of oseltamivir treatment for children with uncomplicated seasonal influenza. J Pediatr. 2012;160(67–73):e6.PubMed Lavelle TA, Uyeki TM, Prosser LA. Cost-effectiveness of oseltamivir treatment for children with uncomplicated seasonal influenza. J Pediatr. 2012;160(67–73):e6.PubMed
32.
go back to reference Lee BY, Bailey RR, Wiringa AE, Assi TM, Beigi RH. Antiviral medications for pregnant women for pandemic and seasonal influenza: an economic computer model. Obstet Gynecol. 2009;114:971–80.PubMedPubMedCentralCrossRef Lee BY, Bailey RR, Wiringa AE, Assi TM, Beigi RH. Antiviral medications for pregnant women for pandemic and seasonal influenza: an economic computer model. Obstet Gynecol. 2009;114:971–80.PubMedPubMedCentralCrossRef
33.
go back to reference Lee BY, Ercius AK, Smith KJ. A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population. Vaccine. 2009;27:2251–7.PubMedPubMedCentralCrossRef Lee BY, Ercius AK, Smith KJ. A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population. Vaccine. 2009;27:2251–7.PubMedPubMedCentralCrossRef
34.
35.
go back to reference Lee BY, Tai JH, Bailey RR, Smith KJ, Nowalk AJ. Economics of influenza vaccine administration timing for children. Am J Manag Care. 2010;16(e75):e85. Lee BY, Tai JH, Bailey RR, Smith KJ, Nowalk AJ. Economics of influenza vaccine administration timing for children. Am J Manag Care. 2010;16(e75):e85.
36.
go back to reference Lee BY, Bailey RR, Wiringa AE, Afriyie A, Wateska AR, Smith KJ, et al. Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza. Vaccine. 2010;28:5952–9.PubMedPubMedCentralCrossRef Lee BY, Bailey RR, Wiringa AE, Afriyie A, Wateska AR, Smith KJ, et al. Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenza. Vaccine. 2010;28:5952–9.PubMedPubMedCentralCrossRef
37.
go back to reference Lee BY, Tai JH, Bailey RR, McGlone SM, Wiringa AE, Zimmer SM, et al. Economic model for emergency use authorization of intravenous peramivir. Am J Manag Care. 2011;17:e1–9.PubMedPubMedCentral Lee BY, Tai JH, Bailey RR, McGlone SM, Wiringa AE, Zimmer SM, et al. Economic model for emergency use authorization of intravenous peramivir. Am J Manag Care. 2011;17:e1–9.PubMedPubMedCentral
38.
go back to reference Lee BY, Bacon KM, Donohue JM, Wiringa AE, Bailey RR, Zimmerman RK. From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination. Vaccine. 2011;29:2149–58.PubMedPubMedCentralCrossRef Lee BY, Bacon KM, Donohue JM, Wiringa AE, Bailey RR, Zimmerman RK. From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination. Vaccine. 2011;29:2149–58.PubMedPubMedCentralCrossRef
39.
go back to reference Lee BY, Stalter RM, Bacon KM, Tai JHY, Bailey RR, Zimmer SM, et al. Cost-effectiveness of adjuvanted versus nonadjuvanted influenza vaccine in adult hemodialysis patients. Am J Kidney Dis. 2011;57:724–32.PubMedPubMedCentralCrossRef Lee BY, Stalter RM, Bacon KM, Tai JHY, Bailey RR, Zimmer SM, et al. Cost-effectiveness of adjuvanted versus nonadjuvanted influenza vaccine in adult hemodialysis patients. Am J Kidney Dis. 2011;57:724–32.PubMedPubMedCentralCrossRef
41.
go back to reference Lee BY, Bartsch SM, Willig AM. Corrigendum to the economic value of a quadrivalent versus trivalent influenza vaccine [Vaccine 30 (2012) 7443–7446]. Vaccine. 2013;31:2477–9.CrossRef Lee BY, Bartsch SM, Willig AM. Corrigendum to the economic value of a quadrivalent versus trivalent influenza vaccine [Vaccine 30 (2012) 7443–7446]. Vaccine. 2013;31:2477–9.CrossRef
42.
go back to reference Lee BY, Tai JHY, McGlone SM, Bailey RR, Wateska AR, Zimmer SM, et al. The potential economic value of a ‘universal’ (multi-year) influenza vaccine. Influenza Other Respir Viruses. 2012;6:167–75.PubMedCrossRef Lee BY, Tai JHY, McGlone SM, Bailey RR, Wateska AR, Zimmer SM, et al. The potential economic value of a ‘universal’ (multi-year) influenza vaccine. Influenza Other Respir Viruses. 2012;6:167–75.PubMedCrossRef
43.
go back to reference Lin HH, Hsu KL, Ko WW, Yang YC, Chang YW, Yu MC, Chen KT. Cost-effectiveness of influenza immunization in adult cancer patients in Taiwan. Clin Microbiol Infect. 2010;16:663–70.PubMedCrossRef Lin HH, Hsu KL, Ko WW, Yang YC, Chang YW, Yu MC, Chen KT. Cost-effectiveness of influenza immunization in adult cancer patients in Taiwan. Clin Microbiol Infect. 2010;16:663–70.PubMedCrossRef
44.
go back to reference Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, et al. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24–59 months in the United States. Vaccine. 2008;26:2841–8.PubMedCrossRef Luce BR, Nichol KL, Belshe RB, Frick KD, Li SX, Boscoe A, et al. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24–59 months in the United States. Vaccine. 2008;26:2841–8.PubMedCrossRef
45.
go back to reference Mamma M, Spandidos DA. Economic evaluation of the vaccination program against seasonal and pandemic A/H1N1 influenza among customs officers in Greece. Health Policy. 2013;109:71–7.PubMedCrossRef Mamma M, Spandidos DA. Economic evaluation of the vaccination program against seasonal and pandemic A/H1N1 influenza among customs officers in Greece. Health Policy. 2013;109:71–7.PubMedCrossRef
46.
go back to reference Michaelidis CI, Zimmerman RK, Nowalk MP, Smith KJ. Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups. Vaccine. 2011;29:3525–30.PubMedCrossRef Michaelidis CI, Zimmerman RK, Nowalk MP, Smith KJ. Estimating the cost-effectiveness of a national program to eliminate disparities in influenza vaccination rates among elderly minority groups. Vaccine. 2011;29:3525–30.PubMedCrossRef
47.
go back to reference Mogasale V, Barendregt J. Cost-effectiveness of influenza vaccination of people aged 50-64 years in Australia: results are inconclusive. Aust N Z J Public Health. 2011;35:180–6.PubMedCrossRef Mogasale V, Barendregt J. Cost-effectiveness of influenza vaccination of people aged 50-64 years in Australia: results are inconclusive. Aust N Z J Public Health. 2011;35:180–6.PubMedCrossRef
48.
go back to reference Myers ER, Misurski DA, Swamy GK. Influence of timing of seasonal influenza vaccination on effectiveness and cost-effectiveness in pregnancy. Am J Obstet Gynecol. 2011;204:S128–40.PubMedCrossRef Myers ER, Misurski DA, Swamy GK. Influence of timing of seasonal influenza vaccination on effectiveness and cost-effectiveness in pregnancy. Am J Obstet Gynecol. 2011;204:S128–40.PubMedCrossRef
49.
go back to reference Newall AT, Scuffham PA, Kelly H, Harsley S, MacIntyre CR. The cost-effectiveness of a universal influenza vaccination program for adults aged 50–64 years in Australia. Vaccine. 2008;26:2142–53.PubMedCrossRef Newall AT, Scuffham PA, Kelly H, Harsley S, MacIntyre CR. The cost-effectiveness of a universal influenza vaccination program for adults aged 50–64 years in Australia. Vaccine. 2008;26:2142–53.PubMedCrossRef
50.
go back to reference Newall AT, Dehollain JP, Creighton P, Beutels P, Wood JG. Understanding the cost-effectiveness of influenza vaccination in children: methodological choices and seasonal variability. Pharmacoeconomics. 2013;31:693–702.PubMedCrossRef Newall AT, Dehollain JP, Creighton P, Beutels P, Wood JG. Understanding the cost-effectiveness of influenza vaccination in children: methodological choices and seasonal variability. Pharmacoeconomics. 2013;31:693–702.PubMedCrossRef
51.
go back to reference Newall AT, Dehollain JP. The cost-effectiveness of influenza vaccination in elderly Australians: an exploratory analysis of the vaccine efficacy required. Vaccine. 2014;32:1323–5.PubMedCrossRef Newall AT, Dehollain JP. The cost-effectiveness of influenza vaccination in elderly Australians: an exploratory analysis of the vaccine efficacy required. Vaccine. 2014;32:1323–5.PubMedCrossRef
52.
go back to reference Nosyk B, Sharif B, Sun H, Cooper C, Anis AH. The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus. PLoS One. 2011;6:e27059.PubMedPubMedCentralCrossRef Nosyk B, Sharif B, Sun H, Cooper C, Anis AH. The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus. PLoS One. 2011;6:e27059.PubMedPubMedCentralCrossRef
53.
go back to reference Patterson BW, Khare RK, Courtney DM, Lee TA, Kyriacou DN. Cost-effectiveness of influenza vaccination of older adults in the ED setting. Am J Emerg Med. 2012;30:1072–9.PubMedCrossRef Patterson BW, Khare RK, Courtney DM, Lee TA, Kyriacou DN. Cost-effectiveness of influenza vaccination of older adults in the ED setting. Am J Emerg Med. 2012;30:1072–9.PubMedCrossRef
54.
go back to reference Pitman RJ, Nagy LD, Sculpher MJ. Cost-effectiveness of childhood influenza vaccination in England and Wales: results from a dynamic transmission model. Vaccine. 2013;31:927–42.PubMedCrossRef Pitman RJ, Nagy LD, Sculpher MJ. Cost-effectiveness of childhood influenza vaccination in England and Wales: results from a dynamic transmission model. Vaccine. 2013;31:927–42.PubMedCrossRef
55.
go back to reference Prosser LA, O’Brien MA, Molinari N-M, Hohman KH, Nichol KL, Messonnier ML, et al. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness. Pharmacoeconomics. 2008;26:163–78.PubMedCrossRef Prosser LA, O’Brien MA, Molinari N-M, Hohman KH, Nichol KL, Messonnier ML, et al. Non-traditional settings for influenza vaccination of adults: costs and cost effectiveness. Pharmacoeconomics. 2008;26:163–78.PubMedCrossRef
56.
go back to reference Prosser LA, Meltzer MI, Fiore A, Epperson S, Bridges CB, Hinrichsen V, et al. Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years. Arch Pediatr Adolesc Med. 2011;165:112–8.PubMedCrossRef Prosser LA, Meltzer MI, Fiore A, Epperson S, Bridges CB, Hinrichsen V, et al. Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years. Arch Pediatr Adolesc Med. 2011;165:112–8.PubMedCrossRef
57.
go back to reference Schmier J, Li S, King JC Jr, Nichol K, Mahadevia PJ. Benefits and costs of immunizing children against influenza at school: an economic analysis based on a large-cluster controlled clinical trial. Health Aff (Millwood). 2008;27:w96–104.PubMedCrossRef Schmier J, Li S, King JC Jr, Nichol K, Mahadevia PJ. Benefits and costs of immunizing children against influenza at school: an economic analysis based on a large-cluster controlled clinical trial. Health Aff (Millwood). 2008;27:w96–104.PubMedCrossRef
58.
go back to reference Skedgel C, Langley JM, MacDonald NE, Scott J, McNeil S. An incremental economic evaluation of targeted and universal influenza vaccination in pregnant women. Can J Public Health. 2011;102:445–50.PubMed Skedgel C, Langley JM, MacDonald NE, Scott J, McNeil S. An incremental economic evaluation of targeted and universal influenza vaccination in pregnant women. Can J Public Health. 2011;102:445–50.PubMed
59.
go back to reference Smolen LJ, Klein TM, Bly CA, Ryan KJ. Cost-effectiveness of live attenuated versus inactivated influenza vaccine among children. Am J Pharm Benefits. 2014;6:171–82. Smolen LJ, Klein TM, Bly CA, Ryan KJ. Cost-effectiveness of live attenuated versus inactivated influenza vaccine among children. Am J Pharm Benefits. 2014;6:171–82.
60.
go back to reference Talbird SE, Brogan AJ, Winiarski AP, Sander B. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States. Am J Health Syst Pharm. 2009;66:469–80.PubMedCrossRef Talbird SE, Brogan AJ, Winiarski AP, Sander B. Cost-effectiveness of treating influenzalike illness with oseltamivir in the United States. Am J Health Syst Pharm. 2009;66:469–80.PubMedCrossRef
61.
go back to reference Talbird SE, Brogan AJ, Winiarski AP. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the US. Am J Prev Med. 2009;37:381–8.PubMedCrossRef Talbird SE, Brogan AJ, Winiarski AP. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the US. Am J Prev Med. 2009;37:381–8.PubMedCrossRef
62.
go back to reference Tarride JE, Burke N, Von Keyserlingk C, O’Reilly D, Xie F, Goeree R. Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents. Clin Outcomes Res. 2012;4:287–98.CrossRef Tarride JE, Burke N, Von Keyserlingk C, O’Reilly D, Xie F, Goeree R. Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents. Clin Outcomes Res. 2012;4:287–98.CrossRef
63.
go back to reference Teufel RJ II, Basco WT Jr, Simpson KN. Cost effectiveness of an inpatient influenza immunization assessment and delivery program for children with asthma. J Hosp Med. 2008;3:134–41.PubMedCrossRef Teufel RJ II, Basco WT Jr, Simpson KN. Cost effectiveness of an inpatient influenza immunization assessment and delivery program for children with asthma. J Hosp Med. 2008;3:134–41.PubMedCrossRef
64.
go back to reference Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS One. 2014;9:e98437.PubMedPubMedCentralCrossRef Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS One. 2014;9:e98437.PubMedPubMedCentralCrossRef
65.
go back to reference Wailoo AJ, Sutton AJ, Cooper NJ, Turner DA, Abrams KR, Brennan A, et al. Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza. Value Health. 2008;11:160–71.PubMedCrossRef Wailoo AJ, Sutton AJ, Cooper NJ, Turner DA, Abrams KR, Brennan A, et al. Cost-effectiveness and value of information analyses of neuraminidase inhibitors for the treatment of influenza. Value Health. 2008;11:160–71.PubMedCrossRef
66.
go back to reference Werker GR, Sharif B, Sun H, Cooper C, Bansback N, Anis AH. Optimal timing of influenza vaccination in patients with human immunodeficiency virus: a Markov cohort model based on serial study participant hemoagglutination inhibition titers. Vaccine. 2014;32:677–84.PubMedCrossRef Werker GR, Sharif B, Sun H, Cooper C, Bansback N, Anis AH. Optimal timing of influenza vaccination in patients with human immunodeficiency virus: a Markov cohort model based on serial study participant hemoagglutination inhibition titers. Vaccine. 2014;32:677–84.PubMedCrossRef
67.
go back to reference You JHS, Wong WCW, Ip M, Lee NLS, Ho SC. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities. J Epidemiol Community Health. 2009;63:906–11.PubMedCrossRef You JHS, Wong WCW, Ip M, Lee NLS, Ho SC. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities. J Epidemiol Community Health. 2009;63:906–11.PubMedCrossRef
68.
go back to reference You JHS, Chan ESK, Leung MYK, Ip M, Lee NLS. A cost-effectiveness analysis of “test” versus “treat” patients hospitalized with suspected influenza in Hong Kong. PLoS One. 2012;7:e33123.PubMedPubMedCentralCrossRef You JHS, Chan ESK, Leung MYK, Ip M, Lee NLS. A cost-effectiveness analysis of “test” versus “treat” patients hospitalized with suspected influenza in Hong Kong. PLoS One. 2012;7:e33123.PubMedPubMedCentralCrossRef
69.
go back to reference You J, Ming WK, Chan P. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. BMC Infect Dis. 2014;14:618.PubMedPubMedCentralCrossRef You J, Ming WK, Chan P. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. BMC Infect Dis. 2014;14:618.PubMedPubMedCentralCrossRef
70.
go back to reference Zhou L, Situ S, Feng Z, Atkins CY, Fung IC, Xu Z, et al. Cost-effectiveness of alternative strategies for annual influenza vaccination among children aged 6 months to 14 years in four provinces in China. PLoS ONE. 2014;9:e87590.PubMedPubMedCentralCrossRef Zhou L, Situ S, Feng Z, Atkins CY, Fung IC, Xu Z, et al. Cost-effectiveness of alternative strategies for annual influenza vaccination among children aged 6 months to 14 years in four provinces in China. PLoS ONE. 2014;9:e87590.PubMedPubMedCentralCrossRef
71.
go back to reference Aboutorabi A, Hadian M, Ghaderi H, Salehi M, Ghiasipour M. Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer. Glob J Health Sci. 2014;7:98–106.PubMedPubMedCentral Aboutorabi A, Hadian M, Ghaderi H, Salehi M, Ghiasipour M. Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer. Glob J Health Sci. 2014;7:98–106.PubMedPubMedCentral
72.
go back to reference Alvarado MD, Mohan AJ, Esserman LJ, Park CC, Harrison BL, Howe RJ, et al. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer. Ann Surg Oncol. 2013;20:2873–80.PubMedCrossRef Alvarado MD, Mohan AJ, Esserman LJ, Park CC, Harrison BL, Howe RJ, et al. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer. Ann Surg Oncol. 2013;20:2873–80.PubMedCrossRef
73.
go back to reference Attard CL, Pepper AN, Brown ST, Thompson MF, Thuresson PO, Yunger S, et al. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. J Med Econ. 2015;18:173–88.PubMedCrossRef Attard CL, Pepper AN, Brown ST, Thompson MF, Thuresson PO, Yunger S, et al. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. J Med Econ. 2015;18:173–88.PubMedCrossRef
74.
go back to reference Au HJ, Golmohammadi K, Younis T, Verma S, Chia S, Fassbender K, et al. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects. Breast Cancer Res Treat. 2009;114:579–87.PubMedCrossRef Au HJ, Golmohammadi K, Younis T, Verma S, Chia S, Fassbender K, et al. Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects. Breast Cancer Res Treat. 2009;114:579–87.PubMedCrossRef
75.
go back to reference Braun S, Mittendorf T, Menschik T, Greiner W, von der Schulenburg JM. Cost effectiveness of exemestane versus tamoxifen in post-menopausal women with early breast cancer in Germany. Breast Care (Basel). 2009;4:389–96.PubMedPubMedCentralCrossRef Braun S, Mittendorf T, Menschik T, Greiner W, von der Schulenburg JM. Cost effectiveness of exemestane versus tamoxifen in post-menopausal women with early breast cancer in Germany. Breast Care (Basel). 2009;4:389–96.PubMedPubMedCentralCrossRef
76.
go back to reference Buendia JA, Vallejos C, Pichon-Riviere A. An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia. Biomedica. 2013;33:411–7.PubMedCrossRef Buendia JA, Vallejos C, Pichon-Riviere A. An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia. Biomedica. 2013;33:411–7.PubMedCrossRef
77.
go back to reference Campbell HE, Epstein D, Bloomfield D, Griffin S, Manca A, Yarnold J, et al. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. Eur J Cancer. 2011;47:2517–30.PubMedCrossRef Campbell HE, Epstein D, Bloomfield D, Griffin S, Manca A, Yarnold J, et al. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. Eur J Cancer. 2011;47:2517–30.PubMedCrossRef
78.
go back to reference Candon D, Healy J, Crown J. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer. Acta Oncol. 2014;53:201–8.PubMedCrossRef Candon D, Healy J, Crown J. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer. Acta Oncol. 2014;53:201–8.PubMedCrossRef
79.
go back to reference Chen W, Jiang Z, Shao Z, Sun Q, Shen K. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value Health. 2009;12(Suppl 3):S82–4.PubMedCrossRef Chen W, Jiang Z, Shao Z, Sun Q, Shen K. An economic evaluation of adjuvant trastuzumab therapy in HER2-positive early breast cancer. Value Health. 2009;12(Suppl 3):S82–4.PubMedCrossRef
80.
go back to reference Delea TE, El-Ouagari K, Karnon J, Sofrygin O. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat. 2008;108:375–87.PubMedCrossRef Delea TE, El-Ouagari K, Karnon J, Sofrygin O. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat. 2008;108:375–87.PubMedCrossRef
81.
go back to reference Delea TE, Taneja C, Sofrygin O, Kaura S, Gnant M. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer. Clin Breast Cancer. 2010;10:267–74.PubMedCrossRef Delea TE, Taneja C, Sofrygin O, Kaura S, Gnant M. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer. Clin Breast Cancer. 2010;10:267–74.PubMedCrossRef
82.
go back to reference Erman A, Nugent A, Amir E, Coyte PC. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2014;145:267–79.PubMedCrossRef Erman A, Nugent A, Amir E, Coyte PC. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer. Breast Cancer Res Treat. 2014;145:267–79.PubMedCrossRef
83.
go back to reference Fonseca M, Araujo GT, Saad ED. Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil. Rev Assoc Med Bras. 2009;55:410–5.PubMedCrossRef Fonseca M, Araujo GT, Saad ED. Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil. Rev Assoc Med Bras. 2009;55:410–5.PubMedCrossRef
84.
go back to reference Gold HT, Hayes MK. Cost effectiveness of new breast cancer radiotherapy technologies in diverse populations. Breast Cancer Res Treat. 2012;136:221–9.PubMedCrossRef Gold HT, Hayes MK. Cost effectiveness of new breast cancer radiotherapy technologies in diverse populations. Breast Cancer Res Treat. 2012;136:221–9.PubMedCrossRef
85.
go back to reference Hall PS, McCabe C, Stein RC, Cameron D. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J Natl Cancer Inst. 2012;104:56–66.PubMedCrossRef Hall PS, McCabe C, Stein RC, Cameron D. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J Natl Cancer Inst. 2012;104:56–66.PubMedCrossRef
86.
go back to reference Hedden L, O’Reilly S, Lohrisch C, Chia S, Speers C, Kovacic L, et al. Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. Oncologist. 2012;17:164–71.PubMedPubMedCentralCrossRef Hedden L, O’Reilly S, Lohrisch C, Chia S, Speers C, Kovacic L, et al. Assessing the real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. Oncologist. 2012;17:164–71.PubMedPubMedCentralCrossRef
87.
go back to reference Ito K, Elkin E, Blinder V, Keating N, Choudhry N. Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer. Cancer. 2013;119:2494–502.PubMedCrossRef Ito K, Elkin E, Blinder V, Keating N, Choudhry N. Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer. Cancer. 2013;119:2494–502.PubMedCrossRef
88.
go back to reference Karnon J, Delea T, Barghout V. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. Eur J Health Econ. 2008;9:171–83.PubMedCrossRef Karnon J, Delea T, Barghout V. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. Eur J Health Econ. 2008;9:171–83.PubMedCrossRef
89.
go back to reference Lee SG, Jee YG, Chung HC, Kim SB, Ro J, Im YH, et al. Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC). Breast Cancer Res Treat. 2009;114:589–95.PubMedCrossRef Lee SG, Jee YG, Chung HC, Kim SB, Ro J, Im YH, et al. Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC). Breast Cancer Res Treat. 2009;114:589–95.PubMedCrossRef
90.
go back to reference Lidgren M, Jonsson B, Rehnberg C, Willking N, Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol. 2008;19:487–95.PubMedCrossRef Lidgren M, Jonsson B, Rehnberg C, Willking N, Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol. 2008;19:487–95.PubMedCrossRef
91.
go back to reference Lipsitz M, Delea TE, Guo A. Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR + early-stage breast cancer. Curr Med Res Opin. 2010;26:2315–28.PubMedCrossRef Lipsitz M, Delea TE, Guo A. Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR + early-stage breast cancer. Curr Med Res Opin. 2010;26:2315–28.PubMedCrossRef
92.
go back to reference Liubao P, Xiaomin W, Chongqing T, Karnon J, Gannong C, Jianhe L, et al. Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide. Pharmacoeconomics. 2009;27:873–86.PubMedCrossRef Liubao P, Xiaomin W, Chongqing T, Karnon J, Gannong C, Jianhe L, et al. Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide. Pharmacoeconomics. 2009;27:873–86.PubMedCrossRef
93.
go back to reference Lux MP, Reichelt C, Wallwiener D, Kreienberg R, Jonat W, Gnant M, et al. Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study. Onkologie. 2010;33:360–8.PubMedCrossRef Lux MP, Reichelt C, Wallwiener D, Kreienberg R, Jonat W, Gnant M, et al. Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study. Onkologie. 2010;33:360–8.PubMedCrossRef
94.
go back to reference Lux MP, Wockel A, Benedict A, Buchholz S, Kreif N, Harbeck N, et al. Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer: a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system. Onkologie. 2010;33:155–66.PubMedCrossRef Lux MP, Wockel A, Benedict A, Buchholz S, Kreif N, Harbeck N, et al. Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer: a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system. Onkologie. 2010;33:155–66.PubMedCrossRef
95.
go back to reference Lux MP, Reichelt C, Karnon J, Tanzer TD, Radosavac D, Fasching PA, et al. Cost-benefit analysis of endocrine therapy in the adjuvant setting for postmenopausal patients with hormone receptor-positive breast cancer, based on survival data and future prices for generic drugs in the context of the german health care system. Breast Care (Basel). 2011;6:381–9.PubMedPubMedCentralCrossRef Lux MP, Reichelt C, Karnon J, Tanzer TD, Radosavac D, Fasching PA, et al. Cost-benefit analysis of endocrine therapy in the adjuvant setting for postmenopausal patients with hormone receptor-positive breast cancer, based on survival data and future prices for generic drugs in the context of the german health care system. Breast Care (Basel). 2011;6:381–9.PubMedPubMedCentralCrossRef
96.
go back to reference Martin-Jimenez M, Rodriguez-Lescure A, Ruiz-Borrego M, Segui-Palmer MA, Brosa-Riestra M. Cost-effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer. Clin Transl Oncol. 2009;11:41–7.PubMedCrossRef Martin-Jimenez M, Rodriguez-Lescure A, Ruiz-Borrego M, Segui-Palmer MA, Brosa-Riestra M. Cost-effectiveness analysis of docetaxel (Taxotere) vs. 5-fluorouracil in combined therapy in the initial phases of breast cancer. Clin Transl Oncol. 2009;11:41–7.PubMedCrossRef
97.
go back to reference Neyt M, Huybrechts M, Hulstaert F, Vrijens F, Ramaekers D. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy. 2008;87:146–59.PubMedCrossRef Neyt M, Huybrechts M, Hulstaert F, Vrijens F, Ramaekers D. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy. 2008;87:146–59.PubMedCrossRef
98.
go back to reference Purmonen TT, Pankalainen E, Turunen JH, Asseburg C, Martikainen JA. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol. 2011;50:344–52.PubMedCrossRef Purmonen TT, Pankalainen E, Turunen JH, Asseburg C, Martikainen JA. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol. 2011;50:344–52.PubMedCrossRef
99.
go back to reference Sasse AD, Sasse EC. Cost-effectiveness analysis of adjuvant anastrozol in post-menopausal women with breast cancer. Rev Assoc Med Bras. 2009;55:535–40.PubMedCrossRef Sasse AD, Sasse EC. Cost-effectiveness analysis of adjuvant anastrozol in post-menopausal women with breast cancer. Rev Assoc Med Bras. 2009;55:535–40.PubMedCrossRef
100.
go back to reference Sher DJ, Wittenberg E, Suh WW, Taghian AG, Punglia RS. Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: a cost-effectiveness analysis. Int J Radiat Oncol Biol Phys. 2009;74:440–6.PubMedCrossRef Sher DJ, Wittenberg E, Suh WW, Taghian AG, Punglia RS. Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: a cost-effectiveness analysis. Int J Radiat Oncol Biol Phys. 2009;74:440–6.PubMedCrossRef
101.
go back to reference Shih V, Chan A, Xie F, Ko Y. Economic evaluation of anastrozole versus tamoxifen for early stage breast cancer in Singapore. Value Health Reg Issues. 2012;1:46–53.CrossRef Shih V, Chan A, Xie F, Ko Y. Economic evaluation of anastrozole versus tamoxifen for early stage breast cancer in Singapore. Value Health Reg Issues. 2012;1:46–53.CrossRef
102.
go back to reference Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat. 2008;109:559–66.PubMedCrossRef Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K. The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. Breast Cancer Res Treat. 2008;109:559–66.PubMedCrossRef
103.
go back to reference Skedgel C, Rayson D, Younis T. Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer? Ann Oncol. 2013;24:1834–40.PubMedCrossRef Skedgel C, Rayson D, Younis T. Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer? Ann Oncol. 2013;24:1834–40.PubMedCrossRef
104.
go back to reference Skedgel C, Rayson D, Younis T. The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial. Value Health. 2009;12:641–8.PubMedCrossRef Skedgel C, Rayson D, Younis T. The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial. Value Health. 2009;12:641–8.PubMedCrossRef
105.
go back to reference Van Vlaenderen I, Canon JL, Cocquyt V, Jerusalem G, Machiels JP, Neven P, et al. Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities. Acta Clin Belg. 2009;64:100–12.PubMedCrossRef Van Vlaenderen I, Canon JL, Cocquyt V, Jerusalem G, Machiels JP, Neven P, et al. Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities. Acta Clin Belg. 2009;64:100–12.PubMedCrossRef
106.
go back to reference Webber-Foster R, Kvizhinadze G, Rivalland G, Blakely T. Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand. Pharmacoeconomics. 2014;32:707–24.PubMedCrossRef Webber-Foster R, Kvizhinadze G, Rivalland G, Blakely T. Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand. Pharmacoeconomics. 2014;32:707–24.PubMedCrossRef
107.
go back to reference Wolowacz SE, Cameron DA, Tate HC, Bagust A. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol. 2008;26:925–33.PubMedCrossRef Wolowacz SE, Cameron DA, Tate HC, Bagust A. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol. 2008;26:925–33.PubMedCrossRef
108.
go back to reference Yang JJ, Park SK, Cho LY, Han W, Park B, Kim H, et al. Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for korean women with breast cancer: retrospective cohort study of the Korean Breast Cancer Society database. Clin Ther. 2010;32:1122–38.PubMedCrossRef Yang JJ, Park SK, Cho LY, Han W, Park B, Kim H, et al. Cost-effectiveness analysis of 5 years of postoperative adjuvant tamoxifen therapy for korean women with breast cancer: retrospective cohort study of the Korean Breast Cancer Society database. Clin Ther. 2010;32:1122–38.PubMedCrossRef
109.
go back to reference Younis T, Rayson D, Sellon M, Skedgel C. Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. Breast Cancer Res Treat. 2008;111:261–7.PubMedCrossRef Younis T, Rayson D, Sellon M, Skedgel C. Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. Breast Cancer Res Treat. 2008;111:261–7.PubMedCrossRef
110.
go back to reference Younis T, Rayson D, Skedgel C. The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer. Curr Oncol. 2011;18:e288–96.PubMedPubMedCentralCrossRef Younis T, Rayson D, Skedgel C. The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer. Curr Oncol. 2011;18:e288–96.PubMedPubMedCentralCrossRef
111.
go back to reference Zendejas B, Moriarty JP, O’Byrne J, Degnim AC, Farley DR, Boughey JC. Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer. J Clin Oncol. 2011;29:2993–3000.PubMedPubMedCentralCrossRef Zendejas B, Moriarty JP, O’Byrne J, Degnim AC, Farley DR, Boughey JC. Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer. J Clin Oncol. 2011;29:2993–3000.PubMedPubMedCentralCrossRef
114.
go back to reference Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB, ISPOR-SMDM Modeling Good Research Practices Task Force. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Value Health. 2012;15:843–50.PubMedCrossRef Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB, ISPOR-SMDM Modeling Good Research Practices Task Force. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Value Health. 2012;15:843–50.PubMedCrossRef
115.
go back to reference Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, ISPOR Task Force on Good Research Practices-Modeling Studies, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6:9–17.PubMedCrossRef Weinstein MC, O’Brien B, Hornberger J, Jackson J, Johannesson M, McCabe C, ISPOR Task Force on Good Research Practices-Modeling Studies, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6:9–17.PubMedCrossRef
116.
go back to reference Campbell HE, Gray AM, Harris AL, Briggs AH, Taylor MA. Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. Br J Cancer. 2010;103:776–86.PubMedPubMedCentralCrossRef Campbell HE, Gray AM, Harris AL, Briggs AH, Taylor MA. Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. Br J Cancer. 2010;103:776–86.PubMedPubMedCentralCrossRef
117.
go back to reference Hoomans T, Severens JL, van der Roer N, Delwel GO. Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands. Pharmacoeconomics. 2012;30:219–27.PubMedCrossRef Hoomans T, Severens JL, van der Roer N, Delwel GO. Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands. Pharmacoeconomics. 2012;30:219–27.PubMedCrossRef
119.
go back to reference Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. CHEERS task force. consolidated health economic evaluation reporting standards (CHEERS) statement. Int J Technol Assess Health Care. 2013;29:117–22.PubMedCrossRef Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. CHEERS task force. consolidated health economic evaluation reporting standards (CHEERS) statement. Int J Technol Assess Health Care. 2013;29:117–22.PubMedCrossRef
120.
go back to reference Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24:355–71.PubMedCrossRef Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24:355–71.PubMedCrossRef
Metadata
Title
Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer
Authors
Pieter T. de Boer
Geert W. J. Frederix
Talitha L. Feenstra
Pepijn Vemer
Publication date
01-09-2016
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 9/2016
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-016-0410-3

Other articles of this Issue 9/2016

PharmacoEconomics 9/2016 Go to the issue